Invivyd (IVVD) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company background and recent milestones

• Focused on protection against viral infectious diseases, initially targeting SARS-CoV-2.

• Pemgarda received Emergency Use Authorization (EUA) in March 2024 and launched commercially in Q2.

• New Chief Commercial Officer, Tim Lee, joined in June to strengthen commercial launch efforts.

• Pemgarda targets immunocompromised patients, especially those with transplants or hematological cancers.

• Exploring expansion to additional immunocompromised groups and next-generation products.

Commercial strategy and financial outlook

• Q2 net product revenue for Pemgarda was $2.3 million; year-end cash expected at $25 million.

• 2024 net product revenue guidance is $150–$200 million, based on 30,000–40,000 doses sold.

• Distribution through major wholesalers with rapid delivery to infusion centers.

• Medicare and Medicaid coverage secured for about 50% of the target population; strong commercial payer uptake.

• Over 100,000 doses available through year-end, with additional supply planned for Q1.

Market access, patient targeting, and education

• Focused on ~1,200 U.S. centers treating immunocompromised patients.

• Sales force remains modest but may expand as patient targeting broadens.

• Education efforts include disease awareness and product benefits for prescribers and infusion clinics.

• Social media campaigns and outreach to care teams and advocacy groups underway.